<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Aliment Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Aliment. Pharmacol. Ther</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2036</journal-id><journal-id journal-id-type="publisher-id">APT</journal-id><journal-title-group><journal-title>Alimentary Pharmacology &#x00026; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0269-2813</issn><issn pub-type="epub">1365-2036</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26228097</article-id><article-id pub-id-type="pmc">5042071</article-id><article-id pub-id-type="doi">10.1111/apt.13334</article-id><article-id pub-id-type="publisher-id">APT13334</article-id><article-categories><subj-group subj-group-type="overline"><subject>Randomised Clinical Trial</subject></subj-group><subj-group subj-group-type="heading"><subject>Randomised Clinical Trials</subject></subj-group></article-categories><title-group><article-title>Randomised clinical trial: the clinical efficacy and safety of an alginate&#x02010;antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (<styled-content style="fixed-case">GERD</styled-content>) in China</article-title><alt-title alt-title-type="left-running-head">J. Sun <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="apt13334-cr-0001" contrib-type="author"><name><surname>Sun</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="apt13334-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt13334-cr-0002" contrib-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="apt13334-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="apt13334-cr-0003" contrib-type="author"><name><surname>Zhao</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="apt13334-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="apt13334-cr-0004" contrib-type="author"><name><surname>Zheng</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="apt13334-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="apt13334-cr-0005" contrib-type="author"><name><surname>Wilkinson</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="apt13334-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="apt13334-cr-0006" contrib-type="author"><name><surname>Ng</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="apt13334-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="apt13334-cr-0007" contrib-type="author" corresp="yes"><name><surname>Yuan</surname><given-names>Y.</given-names></name><xref ref-type="aff" rid="apt13334-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="apt13334-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Ruijin Hospital</named-content><institution>Shanghai Jiaotong University School of Medicine</institution><named-content content-type="city">Shanghai</named-content><country country="CN">China</country></aff><aff id="apt13334-aff-0002"><label><sup>2</sup></label><institution>Shanghai Tongji Hospital</institution><named-content content-type="city">Shanghai</named-content><country country="CN">China</country></aff><aff id="apt13334-aff-0003"><label><sup>3</sup></label><institution>China&#x02010;Japan Friendship Hospital</institution><named-content content-type="city">Beijing</named-content><country country="CN">China</country></aff><aff id="apt13334-aff-0004"><label><sup>4</sup></label><institution>Zhejiang Hospital</institution><named-content content-type="city">Hangzhou</named-content><country country="CN">China</country></aff><aff id="apt13334-aff-0005"><label><sup>5</sup></label><institution>Reckitt Benckiser</institution><named-content content-type="city">Slough</named-content><country country="GB">UK</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold><break/>
Prof. Y. Yuan, Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Rui Jin Er Road, Shanghai 200025, China.<break/>
E&#x02010;mail: <email>yyz28@medmail.com.cn</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2015</year></pub-date><volume>42</volume><issue>7</issue><issue-id pub-id-type="doi">10.1111/apt.2015.42.issue-7</issue-id><fpage>845</fpage><lpage>854</lpage><history><date date-type="received"><day>31</day><month>3</month><year>2015</year></date><date date-type="rev-recd"><day>26</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>06</day><month>7</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2015 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Alimentary Pharmacology &#x00026; Therapeutics Published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:APT-42-845.pdf"/><abstract id="apt13334-abs-0001"><title>Summary</title><sec id="apt13334-sec-0001"><title>Background</title><p>There is a paucity of large&#x02010;scale studies evaluating the clinical benefit of the Gaviscon Double Action (<styled-content style="fixed-case">DA</styled-content>) alginate&#x02010;antacid formulation for treating gastroesophageal reflux disease (<styled-content style="fixed-case">GERD</styled-content>) symptoms.</p></sec><sec id="apt13334-sec-0002"><title>Aim</title><p>Randomised double&#x02010;blind placebo&#x02010;controlled parallel&#x02010;group study to evaluate efficacy and safety of Gaviscon <styled-content style="fixed-case">DA</styled-content> in reducing heartburn, regurgitation and dyspepsia symptoms in individuals with mild&#x02010;to&#x02010;moderate <styled-content style="fixed-case">GERD</styled-content> in China.</p></sec><sec id="apt13334-sec-0003"><title>Methods</title><p>Participants with symptomatic <styled-content style="fixed-case">GERD</styled-content> (<italic>n</italic>&#x000a0;=&#x000a0;1107) were randomised to receive Gaviscon <styled-content style="fixed-case">DA</styled-content> or placebo (two tablets four times daily) for seven consecutive days. The primary endpoint compared the change in Reflux Disease Questionnaire (<styled-content style="fixed-case">RDQ</styled-content>) score for the <styled-content style="fixed-case">GERD</styled-content> (heartburn + regurgitation) dimension between Gaviscon <styled-content style="fixed-case">DA</styled-content> and placebo. Secondary endpoints compared the change in <styled-content style="fixed-case">RDQ</styled-content> scores for individual heartburn, regurgitation and dyspepsia dimensions, overall treatment evaluation (<styled-content style="fixed-case">OTE</styled-content>) scores and incidence of adverse events (<styled-content style="fixed-case">AE</styled-content>s).</p></sec><sec id="apt13334-sec-0004"><title>Results</title><p>Mean <styled-content style="fixed-case">RDQ GERD</styled-content> scores: 2.51 for Gaviscon <styled-content style="fixed-case">DA</styled-content> and 2.50 for placebo at baseline; 1.25 for Gaviscon <styled-content style="fixed-case">DA</styled-content> and 1.46 for placebo post treatment. Gaviscon <styled-content style="fixed-case">DA</styled-content> was statistically superior to placebo in reducing <styled-content style="fixed-case">GERD</styled-content> and dyspepsia <styled-content style="fixed-case">RDQ</styled-content> scores [least&#x02010;squares mean (<styled-content style="fixed-case">LSM</styled-content>) difference: <styled-content style="fixed-case">GERD</styled-content> &#x02212;0.21, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; dyspepsia &#x02212;0.18, <italic>P</italic>&#x000a0;=&#x000a0;0.0004], despite a substantial placebo response. The Gaviscon <styled-content style="fixed-case">DA</styled-content> group reported more favourable overall treatment responses than the placebo group across all <styled-content style="fixed-case">OTE</styled-content> categories (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). Superior relief of <styled-content style="fixed-case">GERD</styled-content> symptoms was observed both in those with non&#x02010;erosive and those with erosive reflux disease (<styled-content style="fixed-case">LSM</styled-content> difference &#x02212;0.14 [<italic>P</italic>&#x000a0;=&#x000a0;0.038] and &#x02212;0.29 [<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001] respectively). Incidence of <styled-content style="fixed-case">AE</styled-content>s was similar in both groups.</p></sec><sec id="apt13334-sec-0005"><title>Conclusion</title><p>Gaviscon <styled-content style="fixed-case">DA</styled-content> tablets provide effective and safe reduction in acid reflux and dyspepsia symptoms in Chinese individuals with mild&#x02010;to&#x02010;moderate <styled-content style="fixed-case">GERD</styled-content>. ClinicalTrials.gov: <styled-content style="fixed-case">NCT</styled-content>01869491</p></sec></abstract><funding-group><award-group><funding-source>Reckitt Benckiser</funding-source></award-group></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>apt13334</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:29.09.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="apt13334-ntgp-0001"><fn id="apt13334-note-0001"><p>
<italic>This article was accepted for publication after full peer&#x02010;review</italic>.</p></fn></fn-group></notes></front><body><sec id="apt13334-sec-0006"><title>Introduction</title><p>Gastroesophageal reflux disease (GERD) is a chronic condition that develops when the reflux of gastric contents into the oesophagus causes troublesome symptoms with or without complications. Heartburn and regurgitation are two of the most common GERD symptoms,<xref rid="apt13334-bib-0001" ref-type="ref">1</xref> with many GERD patients also experiencing dyspepsia.<xref rid="apt13334-bib-0002" ref-type="ref">2</xref> The troublesome symptoms of GERD can have a significant impact on health&#x02010;related quality of life and work productivity.<xref rid="apt13334-bib-0003" ref-type="ref">3</xref>, <xref rid="apt13334-bib-0004" ref-type="ref">4</xref> The prevalence of GERD in East Asia is rising rapidly, although still lower than in the rest of the world.<xref rid="apt13334-bib-0005" ref-type="ref">5</xref>, <xref rid="apt13334-bib-0006" ref-type="ref">6</xref> This places an increasing burden on society and health services in the region.</p><p>Gastroesophageal reflux events and related symptoms commonly occur after meals.<xref rid="apt13334-bib-0007" ref-type="ref">7</xref>, <xref rid="apt13334-bib-0008" ref-type="ref">8</xref> The &#x02018;acid pocket&#x02019; is a zone containing unbuffered, highly acidic gastric secretions that accumulate in the proximal stomach after meals. The acid pocket has been identified as a cause of post&#x02010;prandial acid reflux and represents an attractive target for the treatment of GERD.<xref rid="apt13334-bib-0009" ref-type="ref">9</xref> Proton pump inhibitors (PPIs), which inhibit gastric acid secretion and attenuate acid pocket development,<xref rid="apt13334-bib-0010" ref-type="ref">10</xref> are considered the gold standard treatment for patients with GERD. Despite the high efficacy of PPIs in providing symptom relief via acid suppression, up to a third of patients with GERD fail to respond adequately to PPI therapy.<xref rid="apt13334-bib-0011" ref-type="ref">11</xref> In particular, patients with non&#x02010;erosive reflux disease (NERD) are known to have a lower response rate to PPIs, compared to those with erosive reflux disease (ERD).<xref rid="apt13334-bib-0012" ref-type="ref">12</xref>, <xref rid="apt13334-bib-0013" ref-type="ref">13</xref>, <xref rid="apt13334-bib-0014" ref-type="ref">14</xref>
</p><p>Alginate&#x02010;based formulations act primarily by a unique nonsystemic mechanism of action, different from antacids, PPIs or histamine H2&#x02010;receptor antagonists (H2 antagonists).<xref rid="apt13334-bib-0015" ref-type="ref">15</xref> Upon coming into contact with gastric acid, alginate rapidly forms a gel &#x02018;raft&#x02019; of near&#x02010;neutral pH that creates a protective barrier above the acidic gastric contents. This alginate raft protects the oesophageal mucosa by limiting gastric reflux into the oesophagus.<xref rid="apt13334-bib-0016" ref-type="ref">16</xref>, <xref rid="apt13334-bib-0017" ref-type="ref">17</xref> Alginate&#x02010;based formulations have been shown to act more rapidly than PPIs and H2 antagonists,<xref rid="apt13334-bib-0018" ref-type="ref">18</xref> and to provide longer&#x02010;lasting relief of symptoms than conventional antacids.<xref rid="apt13334-bib-0019" ref-type="ref">19</xref> These formulations have been shown to provide effective relief of upper gastrointestinal (GI) symptoms, either as a monotherapy or in combination treatment. A recent randomised double&#x02010;blind comparative trial showed that Gaviscon suspension, an alginate&#x02010;antacid formulation containing sodium alginate and sodium bicarbonate, was non&#x02010;inferior to omeprazole in achieving a 24&#x02010;h heartburn&#x02010;free period in patients with&#x000a0;moderate GERD.<xref rid="apt13334-bib-0020" ref-type="ref">20</xref> These findings suggest that alginate&#x02010;based formulations could be considered as an alternative or add&#x02010;on therapy in GERD patients, including those with NERD.</p><p>A number of alginate&#x02010;based formulations are currently available on the market. These contain various concentrations of alginate and sodium bicarbonate, as well as other antacid components, and exhibit varying raft strength and acid neutralisation properties.<xref rid="apt13334-bib-0015" ref-type="ref">15</xref>, <xref rid="apt13334-bib-0021" ref-type="ref">21</xref> Gaviscon Double Action [Gaviscon DA; Reckitt Benckiser Healthcare (UK) Limited, Hull, UK] is an alginate&#x02010;antacid formulation with improved raft resilience.<xref rid="apt13334-bib-0021" ref-type="ref">21</xref> It contains sodium alginate and high concentrations of two antacids, calcium carbonate and sodium bicarbonate.<xref rid="apt13334-bib-0022" ref-type="ref">22</xref> Recent studies demonstrated that Gaviscon DA rapidly localises to the post&#x02010;prandial acid pocket and displaces it away from the oesophagus.<xref rid="apt13334-bib-0023" ref-type="ref">23</xref>, <xref rid="apt13334-bib-0024" ref-type="ref">24</xref> Gaviscon DA was found to be significantly superior to antacids in decreasing both acid reflux events<xref rid="apt13334-bib-0024" ref-type="ref">24</xref> and oesophageal acid exposure<xref rid="apt13334-bib-0025" ref-type="ref">25</xref> after meals.</p><p>The clinical benefit of Gaviscon DA was recently demonstrated in a single&#x02010;centre pilot study conducted in participants with GERD in the UK. Gaviscon DA significantly reduced heartburn, regurgitation and dyspepsia symptoms in GERD patients and showed a tolerability profile similar to that of placebo.<xref rid="apt13334-bib-0026" ref-type="ref">26</xref> The present study, a large&#x02010;scale randomised placebo&#x02010;controlled trial, was subsequently conducted in China to assess the efficacy and safety of Gaviscon DA in relieving the GERD&#x02010;related symptoms of heartburn, regurgitation and dyspepsia.</p></sec><sec id="apt13334-sec-0007"><title>Methods</title><sec id="apt13334-sec-0008"><title>Participants and study design</title><p>This was a randomised, double&#x02010;blind, two&#x02010;arm, parallel&#x02010;group, placebo&#x02010;controlled study conducted in the gastroenterology clinics of 31 hospitals across China between June 2013 and May 2014. Participants were recruited from among patients attending the clinics or individuals who visited the clinics to participate in the trial. The trial included individuals who were between 18 and 65&#x000a0;years old (inclusive), who had a diagnosis of uncomplicated symptomatic GERD in accordance with the Montreal definition,<xref rid="apt13334-bib-0001" ref-type="ref">1</xref> as well as a history of frequent episodes of heartburn, regurgitation or dyspepsia symptoms for at least 3&#x000a0;months and on at least 5 of the 7&#x000a0;days prior to screening. Individuals were excluded if they had (i) taken any medications which might interfere with the action of the study medications prior to the start of the study or during the study; (ii) a clinical history or symptom profile suggestive of complicated GERD, other GI diseases (including Barrett's oesophagus, acute peptic ulcer, or indication for <italic>Helicobacter pylori</italic> eradication therapy) or any severe diseases of other major body systems; (iii) any existing conditions that might compromise their safety or participation in the study. Details of the trial eligibility criteria can be found on the ClinicalTrials.gov trial registry website.<xref rid="apt13334-bib-0027" ref-type="ref">27</xref>
</p><p>This study was approved by independent ethics committees and all participants provided written informed consent prior to the initiation of any study&#x02010;related activities. This study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines, and applicable regulatory requirements, and is registered in the ClinicalTrials.gov trial registry (NCT01869491).</p></sec><sec id="apt13334-sec-0009"><title>Treatment allocation and treatment schedule</title><p>Participants were randomly assigned to receive either Gaviscon DA or placebo tablets, based on a computer&#x02010;generated randomisation code list provided by Reckitt Benckiser. Each participant was allocated a unique patient number in sequential order. The study medication was packaged and labelled according to the randomisation code list and issued to the participants with the corresponding patient numbers. Each Gaviscon DA tablet contained 250&#x000a0;mg sodium alginate, 106.5&#x000a0;mg sodium bicarbonate and 187.5&#x000a0;mg calcium carbonate as active ingredients. The placebo tablets contained no active ingredients and were composed mainly of mannitol and xylitol. The placebo tablets matched the Gaviscon DA tablets in appearance, taste and consistency and the study medications were packaged identically. All study personnel and participants were blinded to the treatment allocated. The study was unblinded only after the database had been locked. Participants started treatment the day after their randomisation visit. They took two tablets of the assigned medication four times a day for seven consecutive days: 30&#x000a0;min after breakfast, 30&#x000a0;min after lunch, 30&#x000a0;min after dinner and immediately before lying down for bed.</p></sec><sec id="apt13334-sec-0010"><title>Study assessments</title><p>Efficacy assessments were based on the Reflux Disease Questionnaire (RDQ)<xref rid="apt13334-bib-0028" ref-type="ref">28</xref> and the overall treatment evaluation (OTE).<xref rid="apt13334-bib-0029" ref-type="ref">29</xref>, <xref rid="apt13334-bib-0030" ref-type="ref">30</xref> Participants completed the RDQ before the start of treatment and completed both the RDQ and OTE at the end of treatment. The recall period used for both questionnaires was &#x02018;the last 7&#x000a0;days&#x02019;.</p><p>The RDQ is a 12&#x02010;item self&#x02010;administered questionnaire designed to assess symptom frequency and severity in three dimensions corresponding to heartburn, regurgitation and dyspepsia symptoms. Responses are scored on a six&#x02010;point scale, with higher scores indicating more severe or frequent symptoms.<xref rid="apt13334-bib-0028" ref-type="ref">28</xref> A validated Chinese&#x02010;language version of the RDQ was used in this study.<xref rid="apt13334-bib-0031" ref-type="ref">31</xref> The primary endpoint was the RDQ GERD dimension score, an equally weighed combination of the heartburn and regurgitation dimension scores. This was calculated as the mean of all frequency and intensity scores for the heartburn and regurgitation dimensions, weighted equally. Secondary endpoints included the heartburn, regurgitation and dyspepsia RDQ dimension scores. The change in each RDQ dimension score was calculated as the difference between the baseline and post&#x02010;treatment scores. Changes in RDQ dimension scores (from baseline to post treatment) were then compared between the DA and placebo groups.</p><p>The OTE, a measure of patient responsiveness and satisfaction with treatment, was a further secondary endpoint. The OTE is an instrument designed to assess respondents&#x02019; perceptions of the magnitude of change in their symptoms after treatment and the perceived importance of the change.<xref rid="apt13334-bib-0029" ref-type="ref">29</xref>, <xref rid="apt13334-bib-0030" ref-type="ref">30</xref> Participants were asked to rate their symptoms on a 15&#x02010;point scale: worse (&#x02212;7 to &#x02212;1), unchanged (0), or better (+1 to +7) (Question 1). If participants reported a change in their symptoms, they were asked to rate the importance of the change (Question 2) on a seven&#x02010;point scale, with higher scores indicating greater importance. The percentages of participants in each OTE category were then compared between the DA and placebo groups.</p><p>Safety was assessed based on vital signs and clinical laboratory results, as well as physical examinations before the start of treatment and at the end of treatment. All adverse events (AEs) occurring during the treatment period were documented.</p></sec><sec id="apt13334-sec-0011"><title>Sample size determination</title><p>The sample size for this study was estimated based on the results of an earlier pilot study (GA1203) conducted in the UK.<xref rid="apt13334-bib-0026" ref-type="ref">26</xref> The effect sizes for the RDQ GERD dimension (combined heartburn and regurgitation dimensions) and the dyspepsia dimension were 0.627 and 0.384, respectively, in the pilot study.<xref rid="apt13334-bib-0026" ref-type="ref">26</xref> However, it was anticipated that the effect size in the present Gaviscon DA study would be smaller than in the GA1203 UK pilot study.<xref rid="apt13334-bib-0026" ref-type="ref">26</xref> This was based on observations from a pair of studies conducted in the UK and China on a different alginate&#x02010;antacid formulation, which revealed a much larger placebo effect in the Chinese study population.<xref rid="apt13334-bib-0032" ref-type="ref">32</xref>, <xref rid="apt13334-bib-0033" ref-type="ref">33</xref> The sample size calculation for this study assumed a similar inflated placebo response and therefore a smaller effect size: 0.4 for the RDQ GERD dimension and 0.2 for the dyspepsia dimension. It was estimated that a sample size of at least 1054 participants would be required to detect differences in RDQ scores between the treatment groups with at least 90% power at the 5% significance level. To allow for a 5% dropout rate, it was estimated that 1100 participants would need to be randomised to ensure evaluable data from 1054 participants.</p></sec><sec id="apt13334-sec-0012"><title>Statistical analysis</title><p>The primary endpoint compared the change in RDQ symptom scores for the GERD dimension (from baseline to the end of treatment) between the Gaviscon DA group and the placebo group. The key secondary endpoint compared the change in RDQ symptom scores for the dyspepsia dimension between the DA and placebo groups. Other secondary endpoints included comparisons between the two groups for the following variables: (i) change in RDQ symptom score for individual heartburn and regurgitation dimensions; (ii) scores for both questions of the OTE questionnaire and (iii) incidence of AEs.</p><p>Efficacy analysis was performed for all participants who were enrolled in the study and had at least a partially completed RDQ questionnaire for the study treatment period (intent&#x02010;to&#x02010;treat; ITT population). The primary endpoint (comparison of change in RDQ symptom scores for the GERD dimension between treatment groups) was analysed using a linear mixed model, with &#x02018;treatment&#x02019; as a fixed effect, &#x02018;centre&#x02019; as a random effect and &#x02018;baseline RDQ score for the GERD dimension&#x02019; as a linear covariate. Similarly, linear mixed models were used to compare change from baseline values in RDQ symptom scores for each of the three dimensions (heartburn, regurgitation and dyspepsia) between treatment groups, with the baseline RDQ score for the corresponding dimension used as the covariate. Scores for both OTE questions were summarised by treatment group, and were compared between treatment groups using the Wilcoxon rank&#x02010;sum test stratified by centre. Exploratory analyses of the primary endpoint were also performed for two pre&#x02010;specified subgroups: participants with ERD [Los Angeles (LA) classification grades A or B only] and those with NERD, as confirmed by symptoms and endoscopy findings.<xref rid="apt13334-bib-0034" ref-type="ref">34</xref>
</p><p>Safety analysis was performed for all enrolled participants who received at least one dose of study medication. The incidence of AEs was summarised overall and by relatedness to the study medication, seriousness and severity. The incidence of AEs in the treatment groups was compared using Fisher's exact test.</p><p>All statistical analyses were conducted using two&#x02010;tailed tests at the 5% significance level. A closed testing procedure was applied to preserve the type 1 (false positive) error rate of 5% for the key secondary endpoint. A significant comparison at the 5% level for this key secondary endpoint was considered as confirmatory evidence only if the primary endpoint was also significant at the 5% level. All other secondary endpoints and any alternate analyses for the primary and key secondary endpoints were considered supportive only and no further adjustment for multiple comparisons was made. All analyses were conducted using <sc>sas</sc>, version 9.2 (SAS Institute Inc., Cary, NC, USA).</p></sec></sec><sec id="apt13334-sec-0013"><title>Results</title><sec id="apt13334-sec-0014"><title>Participant demographics and baseline characteristics</title><p>A total of 1107 participants were enrolled and randomised to treatment (Figure&#x000a0;<xref rid="apt13334-fig-0001" ref-type="fig">1</xref>). Of these, 1099 participants received at least one dose of study medication and were included in the safety population. Thirty&#x02010;four participants did not answer the RDQ questionnaire at the end of the treatment; the remaining 1073 participants were included in the efficacy evaluation (ITT population): 536 in the Gaviscon DA group and 537 in the placebo group. A total of 1062 participants completed the study. The flow of participants through the trial and the reasons for withdrawal from the trial are summarised in Figure&#x000a0;<xref rid="apt13334-fig-0001" ref-type="fig">1</xref>. Demographics and baseline characteristics, including GERD status (presence of ERD or NERD) were similar in the Gaviscon DA and placebo groups (Table&#x000a0;<xref rid="apt13334-tbl-0001" ref-type="table-wrap">1</xref>). At baseline, the DA and placebo groups had similar scores in the GERD RDQ dimension as well as in the individual heartburn, regurgitation and dyspepsia dimensions (Table&#x000a0;<xref rid="apt13334-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="apt13334-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and baseline characteristics of participants (ITT population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="char" valign="top" rowspan="1" colspan="1">Gaviscon DA (<italic>n</italic>&#x000a0;=&#x000a0;536)</th><th align="char" valign="top" rowspan="1" colspan="1">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;537)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years), mean (s.d.)</td><td align="char" char="(" rowspan="1" colspan="1">45.0 (11.8)</td><td align="char" char="(" rowspan="1" colspan="1">45.0 (11.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">261 (48.7)</td><td align="char" char="(" rowspan="1" colspan="1">284 (52.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), median (range)</td><td align="char" char="(" rowspan="1" colspan="1">23.4 (16.0&#x02013;34.9)</td><td align="char" char="(" rowspan="1" colspan="1">23.3 (16.6&#x02013;32.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker, <italic>n</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">97 (18.1)</td><td align="char" char="(" rowspan="1" colspan="1">90 (16.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Alcohol use, <italic>n</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">63 (11.8)</td><td align="char" char="(" rowspan="1" colspan="1">63 (11.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">ERD<xref ref-type="fn" rid="apt13334-note-0003">a</xref>, <italic>n</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">259 (48.3)</td><td align="char" char="(" rowspan="1" colspan="1">251 (46.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">LA grade A, <italic>n</italic> (%)<xref ref-type="fn" rid="apt13334-note-0004">b</xref>
</td><td align="char" char="(" rowspan="1" colspan="1">203 (78.4)</td><td align="char" char="(" rowspan="1" colspan="1">197 (78.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">LA grade B, <italic>n</italic> (%)<xref ref-type="fn" rid="apt13334-note-0004">b</xref>
</td><td align="char" char="(" rowspan="1" colspan="1">56 (21.6)</td><td align="char" char="(" rowspan="1" colspan="1">54 (21.5)</td></tr></tbody></table><table-wrap-foot><fn id="apt13334-note-0002"><p>BMI, body mass index; ERD, erosive reflux disease; ITT, intent&#x02010;to&#x02010;treat; LA grade, Los Angeles classification grade; GERD, gastroesophageal reflux disease; RDQ, reflux disease questionnaire.</p></fn><fn id="apt13334-note-0003"><label>a</label><p>Presence of ERD was confirmed by endoscopy. Patients with severe ERD (Los Angeles classification grades C or D) were excluded from this study.</p></fn><fn id="apt13334-note-0004"><label>b</label><p>Percentages are expressed with respect to the group of patients with ERD/abnormal endoscopy findings.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="apt13334-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline and end of treatment RDQ scores (ITT population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">RDQ dimension score</th><th align="char" valign="top" rowspan="1" colspan="1">Gaviscon DA (<italic>n</italic>&#x000a0;=&#x000a0;536)</th><th align="char" valign="top" rowspan="1" colspan="1">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;537)</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">GERD (combined heartburn and regurgitation)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Baseline score</td><td align="char" char="." rowspan="1" colspan="1">2.51 (0.93)</td><td align="char" char="." rowspan="1" colspan="1">2.50 (0.94)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range of scores</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Post&#x02010;treatment score</td><td align="char" char="." rowspan="1" colspan="1">1.25 (0.94)</td><td align="char" char="." rowspan="1" colspan="1">1.46 (1.00)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range of scores</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;4.9</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;4.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Min/max score change from baseline</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;4.6&#x02013;1.5</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;4.0&#x02013;1.4</td></tr><tr><td align="left" colspan="3" rowspan="1">Heartburn</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Baseline score</td><td align="char" char="." rowspan="1" colspan="1">2.37 (1.33)</td><td align="char" char="." rowspan="1" colspan="1">2.30 (1.35)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range of scores</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Post&#x02010;treatment score</td><td align="char" char="." rowspan="1" colspan="1">1.20 (1.15)</td><td align="char" char="." rowspan="1" colspan="1">1.38 (1.24)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range of scores</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Min/max score change from baseline</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;4.5&#x02013;2.5</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;4.5&#x02013;2.0</td></tr><tr><td align="left" colspan="3" rowspan="1">Regurgitation</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Baseline score</td><td align="char" char="." rowspan="1" colspan="1">2.65 (1.26)</td><td align="char" char="." rowspan="1" colspan="1">2.70 (1.25)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range of scores</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Post&#x02010;treatment score</td><td align="char" char="." rowspan="1" colspan="1">1.30 (1.13)</td><td align="char" char="." rowspan="1" colspan="1">1.54 (1.21)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range of scores</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Min/max score change from baseline</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.0, 1.0</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;4.5&#x02013;2.5</td></tr><tr><td align="left" colspan="3" rowspan="1">Dyspepsia</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Baseline score</td><td align="char" char="." rowspan="1" colspan="1">2.02 (1.39)</td><td align="char" char="." rowspan="1" colspan="1">2.02 (1.36)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range of scores</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Post&#x02010;treatment score</td><td align="char" char="." rowspan="1" colspan="1">1.04 (1.10)</td><td align="char" char="." rowspan="1" colspan="1">1.22 (1.14)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Range of scores</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td><td align="char" char="." rowspan="1" colspan="1">0.0&#x02013;5.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Min/max score change from baseline</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.0&#x02013;2.8</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.0&#x02013;2.3</td></tr></tbody></table><table-wrap-foot><fn id="apt13334-note-0005"><p>RDQ, reflux disease questionnaire; ITT, intent&#x02010;to&#x02010;treat; DA, Double Action; GERD, gastroesophageal reflux disease.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="apt13334-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study participant disposition. <styled-content style="fixed-case">AE</styled-content>, adverse event; <styled-content style="fixed-case">SAE</styled-content>, serious adverse event; <styled-content style="fixed-case">DA</styled-content>, Double Action.</p></caption><graphic id="nlm-graphic-1" xlink:href="APT-42-845-g001"/></fig></sec><sec id="apt13334-sec-0015"><title>Efficacy</title><p>At baseline, the mean (s.d.) RDQ score for the GERD dimension was 2.51 (0.93) in the DA group and 2.50 (0.94) in the placebo group (Table&#x000a0;<xref rid="apt13334-tbl-0002" ref-type="table-wrap">2</xref>). The range of baseline GERD RDQ scores was the same in both groups (0&#x02013;5). At the end of the 7&#x02010;day treatment period, GERD RDQ scores were lower in both groups: 1.25 (0.94) for the DA group and 1.46 (1.00) for placebo [mean (s.d.)]. These correspond to mean score changes of &#x02212;1.26 (DA) and &#x02212;1.06 (placebo). The magnitude of the GERD RDQ score change (post&#x02010;treatment score minus baseline score) ranged from &#x02212;4.6 to 1.5 in the DA group, compared with &#x02212;4.0 to 1.4 in the placebo group (Table&#x000a0;<xref rid="apt13334-tbl-0002" ref-type="table-wrap">2</xref>). For the dyspepsia endpoint, mean RDQ scores decreased from 2.02 at baseline to 1.04 post treatment in the DA group, and from 2.02 to 1.22 in the placebo group (Table&#x000a0;<xref rid="apt13334-tbl-0002" ref-type="table-wrap">2</xref>). In both the GERD and dyspepsia RDQ dimensions, the placebo response was considerably larger than that seen in the pilot study.</p><p>Adjusted changes in RDQ score for the GERD dimension and the individual RDQ dimensions at the end of treatment are summarised in Table&#x000a0;<xref rid="apt13334-tbl-0003" ref-type="table-wrap">3</xref>. At the end of the treatment period, there was a decrease in GERD RDQ score in both treatment groups, with a least&#x02010;squares mean (LSM) change of &#x02212;1.27 for Gaviscon DA and &#x02212;1.06 for placebo. The decrease in RDQ score was significantly greater for Gaviscon DA than placebo, with a LSM difference of &#x02212;0.21 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). Decreases were also observed in scores for the individual RDQ dimensions (heartburn, regurgitation and dyspepsia) at the end of treatment, with significantly greater reductions in the Gaviscon DA group than the placebo group (Table&#x000a0;<xref rid="apt13334-tbl-0003" ref-type="table-wrap">3</xref>).</p><table-wrap id="apt13334-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Adjusted change in RDQ score for the GERD dimension and the individual RDQ dimensions from baseline to the end of treatment (ITT population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">RDQ dimension</th><th align="char" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">LSM change (95% CI)</th><th align="char" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">LSM difference<xref ref-type="fn" rid="apt13334-note-0007">a</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="char" valign="top" rowspan="1" colspan="1">Gaviscon DA (<italic>n</italic>&#x000a0;=&#x000a0;536)</th><th align="char" valign="top" rowspan="1" colspan="1">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;537)</th><th align="char" valign="top" rowspan="1" colspan="1">(95% CI); <italic>P</italic>&#x02010;value<xref ref-type="fn" rid="apt13334-note-0008">b</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">GERD (heartburn + regurgitation)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1.27 (&#x02212;1.37 to &#x02212;1.16)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1.06 (&#x02212;1.17 to &#x02212;0.95)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.21 (&#x02212;0.31 to &#x02212;0.11); <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Heartburn</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1.16 (&#x02212;1.28 to &#x02212;1.04)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.95 (&#x02212;1.07 to &#x02212;0.83)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.21 (&#x02212;0.32 to &#x02212;0.10); <italic>P</italic>&#x000a0;=&#x000a0;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Regurgitation</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1.37 (&#x02212;1.48 to &#x02212;1.26)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1.16 (&#x02212;1.27 to &#x02212;1.05)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.21 (&#x02212;0.32 to &#x02212;0.09); <italic>P</italic>&#x000a0;=&#x000a0;0.0004</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspepsia</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.98 (&#x02212;1.10 to &#x02212;0.86)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.80 (&#x02212;0.91 to &#x02212;0.68)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.18 (&#x02212;0.29 to &#x02212;0.08); <italic>P</italic>&#x000a0;=&#x000a0;0.0004</td></tr></tbody></table><table-wrap-foot><fn id="apt13334-note-0006"><p>CI, confidence interval; GERD, gastroesophageal reflux disease; LSM, least&#x02010;squares mean; RDQ, reflux disease questionnaire; DA, Double Action; ITT, intent&#x02010;to&#x02010;treat.</p></fn><fn id="apt13334-note-0007"><label>a</label><p>LSM difference is the difference in RDQ score changes between treatment groups (LSM change for Gaviscon DA group minus LSM change for placebo group).</p></fn><fn id="apt13334-note-0008"><label>b</label><p>
<italic>P</italic>&#x02010;value for comparison between treatment groups.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Within the ERD and NERD subgroups, mean baseline GERD RDQ scores were similar in the DA and placebo groups (Table&#x000a0;<xref rid="apt13334-tbl-0004" ref-type="table-wrap">4</xref>). Changes in RDQ score for the GERD dimension for the ERD and NERD subgroups are summarised in Table&#x000a0;<xref rid="apt13334-tbl-0004" ref-type="table-wrap">4</xref>. In both subgroups, decreases in GERD RDQ score were observed at the end of treatment. Furthermore, reductions in GERD RDQ score were significantly greater among participants receiving Gaviscon DA than among those receiving placebo in both the ERD and NERD subgroups. The LSM difference between Gaviscon DA and placebo was &#x02212;0.29 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) in the ERD subgroup and &#x02212;0.14 (<italic>P</italic>&#x000a0;=&#x000a0;0.038) in the NERD subgroup.</p><table-wrap id="apt13334-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Adjusted change in RDQ score for the GERD dimension (combined heartburn and regurgitation dimensions) for NERD and ERD subgroups (ITT population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Subgroup</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">LSM change (95% CI)</th><th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">LSM difference<xref ref-type="fn" rid="apt13334-note-0010">a</xref> (95%CI); <italic>P</italic>&#x02010;value<xref ref-type="fn" rid="apt13334-note-0011">b</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Gaviscon DA</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo</th><th align="left" valign="top" rowspan="1" colspan="1">Gaviscon DA&#x000a0;&#x02212;&#x000a0;Placebo</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ERD</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;259</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;251</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Baseline score</td><td align="left" rowspan="1" colspan="1">2.62</td><td align="left" rowspan="1" colspan="1">2.52</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Post&#x02010;treatment score</td><td align="left" rowspan="1" colspan="1">1.31</td><td align="left" rowspan="1" colspan="1">1.55</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LSM change (95% CI)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.33 (&#x02212;1.47 to &#x02212;1.18)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.04 (&#x02212;1.18 to &#x02212;0.89)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.29 (&#x02212;0.43 to &#x02212;0.14); <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">NERD</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;277</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;286</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Baseline score</td><td align="left" rowspan="1" colspan="1">2.41</td><td align="left" rowspan="1" colspan="1">2.49</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Post&#x02010;treatment score</td><td align="left" rowspan="1" colspan="1">1.20</td><td align="left" rowspan="1" colspan="1">1.38</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">LSM change (95% CI)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.22 (&#x02212;1.36 to &#x02212;1.09)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.09 (&#x02212;1.22 to &#x02212;0.96)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.14 (&#x02212;0.27 to &#x02212;0.01); <italic>P</italic>&#x000a0;=&#x000a0;0.038</td></tr></tbody></table><table-wrap-foot><fn id="apt13334-note-0009"><p>CI, confidence interval; ERD, erosive reflux disease; GERD, gastroesophageal reflux disease; LSM, least&#x02010;squares mean; ITT, intent&#x02010;to&#x02010;treat; NERD, non&#x02010;erosive reflux disease; DA, Double Action; RDQ, reflux disease questionnaire.</p></fn><fn id="apt13334-note-0010"><label>a</label><p>LSM difference is the difference in RDQ score changes between treatment groups (LSM change for Gaviscon DA group minus LSM change for placebo group).</p></fn><fn id="apt13334-note-0011"><label>b</label><p>
<italic>P</italic>&#x02010;value for comparison between treatment groups.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Based on the OTE assessments, the majority of participants in both the DA (90.3%) and placebo (84.2%) groups experienced an improvement in their symptoms following treatment (OTE responses from &#x02018;+1 &#x02013; Hardly any better&#x02019; to &#x02018;+7 &#x02013; A very great deal better&#x02019;; Question 1) (Table&#x000a0;S1). Moreover, over half (52.2%) of participants in the DA group rated their symptoms as at least &#x02018;Moderately better&#x02019; (OTEs from +4 to +7), compared to 39.2% of the placebo group. Across all OTE response categories, participants in the Gaviscon DA group reported a more favourable overall treatment response (Question 1) than those in the placebo group (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; Wilcoxon rank&#x02010;sum test stratified by centre). This improvement in symptoms was perceived as important (Question 2) by the majority of participants in both groups (Gaviscon DA 96.3%, placebo 95.1%).</p><p>Figure&#x000a0;<xref rid="apt13334-fig-0002" ref-type="fig">2</xref> shows the observed relationship between the mean reduction in RDQ dimension scores for GERD and dyspepsia and participants&#x02019; overall rating of their response to treatment (OTE response category). This allows numerical changes in RDQ score to be interpreted in terms of the degree of improvement reported by participants. In the GERD RDQ dimension, the mean score change of &#x02212;1.27 in the DA group corresponded to an OTE of between &#x02018;4 &#x02013; Moderately better&#x02019; and &#x02018;3 &#x02013; Somewhat better&#x02019;. The smaller GERD RDQ score reduction in the placebo group (&#x02212;1.06) corresponded to a less favourable OTE of between &#x02018;3 &#x02013; Somewhat better&#x02019; and &#x02018;2 &#x02013; A little better&#x02019; (Figure&#x000a0;<xref rid="apt13334-fig-0002" ref-type="fig">2</xref>). Similarly, the mean score reduction in the dyspepsia RDQ dimension for the DA group (0.98) corresponded to a more favourable OTE than the mean score reduction for the placebo group (0.80).</p><fig fig-type="Figure" xml:lang="en" id="apt13334-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Relationship between reduction in <styled-content style="fixed-case">RDQ</styled-content> dimension scores and participants&#x02019; overall rating of their response to treatment (<styled-content style="fixed-case">OTE</styled-content> Question 1). Results shown are for participants who reported improvement in symptoms (<styled-content style="fixed-case">OTE</styled-content> Question 1). &#x02018;G&#x02019; and &#x02018;P&#x02019; denote the mean <styled-content style="fixed-case">RDQ</styled-content> score change from baseline for the Gaviscon <styled-content style="fixed-case">DA</styled-content> and Placebo groups, respectively. <styled-content style="fixed-case">GERD</styled-content>, gastroesophageal reflux disease; <styled-content style="fixed-case">OTE</styled-content>, overall treatment evaluation; <styled-content style="fixed-case">DA</styled-content>, Double Action.</p></caption><graphic id="nlm-graphic-3" xlink:href="APT-42-845-g002"/></fig></sec><sec id="apt13334-sec-0016"><title>Safety</title><p>Adverse events reported during treatment are summarised in Table&#x000a0;<xref rid="apt13334-tbl-0005" ref-type="table-wrap">5</xref>. The incidence of AEs was similar in the Gaviscon DA and placebo groups. Seventy&#x02010;four participants (13.5%) in the Gaviscon DA group and 63 participants (11.5%) in the placebo group experienced AEs during treatment. Twenty&#x02010;nine participants (5.3%) in the Gaviscon DA group and 19 participants (3.5%) in the placebo group had AEs that were at least possibly related to the study medication. Most of these AEs were GI disorders such as constipation, abdominal distension, flatulence and nausea (Table&#x000a0;S2). One participant (0.2%) in the Gaviscon DA group reported a serious AE. Two participants [one in each group (0.2%)] had severe AEs. Treatment discontinuation due to AEs was reported for two participants (0.4%) in the Gaviscon DA group and four participants (0.7%) in the placebo group. No deaths or significant laboratory findings were reported during the study. No significant changes in vital signs were observed in either group.</p><table-wrap id="apt13334-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Incidence of AEs in Gaviscon DA and placebo groups (safety population)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Adverse events</th><th align="char" valign="top" rowspan="1" colspan="1">Gaviscon DA (<italic>n</italic>&#x000a0;=&#x000a0;549) <italic>n</italic> (%)</th><th align="char" valign="top" rowspan="1" colspan="1">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;550) <italic>n</italic> (%)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;value<xref ref-type="fn" rid="apt13334-note-0013">a</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any AE</td><td align="char" char="." rowspan="1" colspan="1">74 (13.5)</td><td align="char" char="." rowspan="1" colspan="1">63 (11.5)</td><td align="left" rowspan="1" colspan="1">0.317</td></tr><tr><td align="left" rowspan="1" colspan="1">Any related AE</td><td align="char" char="." rowspan="1" colspan="1">29 (5.3)</td><td align="char" char="." rowspan="1" colspan="1">19 (3.5)</td><td align="left" rowspan="1" colspan="1">0.143</td></tr><tr><td align="left" rowspan="1" colspan="1">Any SAE</td><td align="char" char="." rowspan="1" colspan="1">1 (0.2)</td><td align="char" char="." rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" rowspan="1" colspan="1">Any severe AE</td><td align="char" char="." rowspan="1" colspan="1">1 (0.2)</td><td align="char" char="." rowspan="1" colspan="1">1 (0.2)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Any AE leading to discontinuation of study medication</td><td align="char" char="." rowspan="1" colspan="1">2 (0.4)</td><td align="char" char="." rowspan="1" colspan="1">4 (0.7)</td><td align="left" rowspan="1" colspan="1">&#x02212;</td></tr></tbody></table><table-wrap-foot><fn id="apt13334-note-0012"><p>AE, adverse event; SAE, serious adverse event; DA, Double Action.</p></fn><fn id="apt13334-note-0013"><label>a</label><p>
<italic>P</italic>&#x02010;value for comparison between treatment groups.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec id="apt13334-sec-0017"><title>Discussion</title><p>This study is the first large&#x02010;scale randomised, double&#x02010;blind, placebo&#x02010;controlled clinical trial to evaluate treatment with Gaviscon DA tablets for relief of heartburn, regurgitation and dyspepsia symptoms in individuals with GERD. Treatment with Gaviscon DA significantly decreased GERD and dyspepsia symptoms, as assessed by the change in RDQ dimension scores. Reductions in GERD and dyspepsia scores were also observed in the placebo group following treatment; this placebo response was considerably larger than that seen in the earlier UK pilot study.<xref rid="apt13334-bib-0026" ref-type="ref">26</xref> In spite of this enhanced placebo response, Gaviscon DA was statistically superior to placebo for all primary and secondary endpoints. There was no evidence to suggest any inconsistency in treatment effects across the 31 study centres in China.</p><p>Participants who received Gaviscon DA reported significantly greater overall improvement in their symptoms (higher OTE ratings) after the 7&#x02010;day treatment than those who received placebo. The mean reductions in GERD and dyspepsia RDQ scores in the DA group also corresponded to more favourable OTE ratings than the reductions seen in the placebo group. Overall, the number of serious or severe AEs was low and incidence of AEs was similar in the Gaviscon DA and placebo groups. These AEs were not deemed to be related to the study medication. The incidence of discontinuation due to AEs was very low (&#x0003c;1%) and was similar in the two groups.</p><p>Study participants were recruited from among attendees of 31 gastroenterology clinics across China, and are likely to be representative of the local population of patients with mild&#x02010;to&#x02010;moderate symptomatic GERD. Patients with severe ERD (LA classification grade C or D) were excluded from this study, and therefore the findings may not be generalisable to patients with more severe disease. Due to the short study duration, the findings are primarily applicable to situations involving short&#x02013;term treatment of GERD symptoms, whereas individuals with severe or chronic disease might be more likely to receive long&#x02010;term treatment with multiple types of medication. This study did not include follow&#x02010;up or extension of treatment after the end of the study period. The maximum dose of Gaviscon DA is four tablets four times daily.<xref rid="apt13334-bib-0022" ref-type="ref">22</xref> Although the minimum dose (two tablets four times daily) was used in this study to maximise compliance, a statistically significantly greater improvement was still observed in the active treatment group.</p><p>The small differential benefit (DA vs. placebo) in this study can be attributed to the large placebo response observed in this Chinese GERD patient population. This is apparent when the results are compared with those of the UK pilot study (GA1203)<xref rid="apt13334-bib-0026" ref-type="ref">26</xref> that employed similar endpoints. In this study, the primary endpoint was the reduction in the RDQ GERD score following a 7&#x02010;day treatment, with LS mean reductions of 1.27 for Gaviscon DA and 1.06 for placebo. In contrast, the corresponding LS mean reductions for this endpoint in the UK pilot study<xref rid="apt13334-bib-0026" ref-type="ref">26</xref> were 1.35 for Gaviscon DA and 0.82 for placebo.</p><p>In a Chinese study (GA0917)<xref rid="apt13334-bib-0033" ref-type="ref">33</xref> involving a different Gaviscon formulation, 77% of participants taking the active treatment reported improvement in symptoms following 1&#x000a0;week of treatment, compared to 67% in the blinded placebo group. This was a considerably higher placebo response rate than that seen in an open&#x02010;label UK study (0100901)<xref rid="apt13334-bib-0032" ref-type="ref">32</xref> with similar endpoints, in which 74% of those taking the active treatment reported some improvement in symptoms following 2&#x000a0;weeks of treatment, compared to only 44% of the nonblinded placebo group.</p><p>It should be noted that, in both pairs of studies, the benefit in the active treatment group was reasonably similar across the UK and China study populations, despite the differences in study settings and patient populations. This suggests that the differential benefit (active treatment minus placebo) was smaller in the China studies due to the inflated placebo response. These observations in Chinese patient populations add to the well&#x02010;known placebo effects already documented in GERD studies.<xref rid="apt13334-bib-0035" ref-type="ref">35</xref> Further research will be needed to understand the factors contributing to the large placebo response among Chinese study participants.</p><p>To permit the detection of a smaller treatment effect against the background of the anticipated large placebo response, the present study was deliberately over&#x02010;powered in the sample size calculations, which assumed a smaller effect size than in the pilot study. It is possible that additional measures, such as including participants with more severe or frequent GERD symptoms, including more participants with erosive GERD, and/or using the maximum dose of Gaviscon DA (four tablets four times daily), might have made it possible to demonstrate a larger relative benefit for the active treatment.</p><p>Pre&#x02010;specified subgroup analyses indicated that, although a greater response was observed in participants with ERD, Gaviscon DA could provide significant symptomatic relief for GERD and dyspepsia in both ERD and NERD. This may be of clinical interest, as the effectiveness of PPI treatment is known to be more limited in patients with NERD.<xref rid="apt13334-bib-0012" ref-type="ref">12</xref> The findings of this study are consistent with those from smaller randomised controlled studies of other alginate&#x02010;based formulations in Chinese and Japanese NERD patients, which suggested that alginate&#x02010;based formulations may be effective for relieving GERD symptoms in NERD patients, either as a monotherapy or in combination treatment.<xref rid="apt13334-bib-0013" ref-type="ref">13</xref>, <xref rid="apt13334-bib-0014" ref-type="ref">14</xref>
</p><p>Taken together, the results of this study and those of the earlier UK pilot study<xref rid="apt13334-bib-0026" ref-type="ref">26</xref> demonstrate that Gaviscon DA is safe and effective for short&#x02010;term treatment of GERD and dyspepsia symptoms. Improvements in GERD symptoms following 7&#x02010;day treatment with Gaviscon DA were statistically significant superior to placebo, despite a substantial placebo response. Subgroup analysis provided evidence for modest but significantly greater symptomatic improvement with Gaviscon DA compared to placebo in both NERD and ERD subgroups. No safety issues were observed with Gaviscon DA treatment, which showed placebo&#x02010;like tolerability. These findings suggest that Gaviscon DA tablets may be a reasonable alternative or add&#x02010;on treatment option for patients with mild&#x02010;to&#x02010;moderate symptomatic GERD.</p></sec><sec id="apt13334-sec-0018"><title>Authorship</title><p>
<italic>Guarantor of the article</italic>: Prof. Yaozong Yuan.<italic>Author contributions</italic>: J Sun, Y Yuan, C Yang, H Zhao and P Zheng were responsible for data acquisition and revision of the article for important intellectual content. J&#x000a0;Wilkinson was responsible for conception and design of the trial, data interpretation and revision of the article for important intellectual content. B&#x000a0;Ng was responsible for data interpretation and revision of the article for important intellectual content. All authors approved the final version of the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;S1.</bold> Overall treatment evaluation (OTE) in DA and placebo groups.</p><p>
<bold>Table&#x000a0;S2.</bold> Number of patients experiencing at least one study product&#x02010;related adverse event.</p></caption><media xlink:href="APT-42-845-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="apt13334-sec-0019"><title>Acknowledgments</title><p>The authors thank all the patients who participated in this study. The authors also gratefully acknowledge L Huo, M Cui, N Dai, J Fang, J Cai, B Wang, L Li, J Chen, T Han, X Guo, J Guo, J Sheng, J Hu, L Lu, D Wu, S Zhang, R Wang, D Zou, Y Li, J Ren, Y Lan, H Xu, S Chen, K Wu, C Tang, Y Yang, J Liu and G Tang for their contributions to this study, as well as G Smith and L Rowe (Reckitt Benckiser, UK) for critical review of the manuscript.<italic>Declaration of personal interests</italic>: B Ng and J Wilkinson are employees of Reckitt Benckiser (UK). All other authors declare that they have no relevant interests to disclose.<italic>Declaration of funding interests</italic>: This study was funded in full by Reckitt Benckiser. Writing support was provided by Tech Observer and was funded by Reckitt Benckiser.</p></ack><ref-list content-type="cited-references" id="apt13334-bibl-0001"><title>References</title><ref id="apt13334-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="apt13334-cit-0001">
<string-name>
<surname>Vakil</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>van Zanten</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Kahrilas</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dent</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>R</given-names>
</string-name>. <article-title>The Montreal definition and classification of gastroesophageal reflux disease: a global evidence&#x02010;based consensus</article-title>. <source>Am J Gastroenterol</source>
<year>2006</year>; <volume>101</volume>: <fpage>1900</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">16928254</pub-id></mixed-citation></ref><ref id="apt13334-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="apt13334-cit-0002">
<string-name>
<surname>Guillemot</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ducrotte</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bueno</surname>
<given-names>L</given-names>
</string-name>. <article-title>Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice</article-title>. <source>Gastroenterol Clin Biol</source>
<year>2005</year>; <volume>29</volume>: <fpage>243</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15864173</pub-id></mixed-citation></ref><ref id="apt13334-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="apt13334-cit-0003">
<string-name>
<surname>Gisbert</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Karagiannis</surname>
<given-names>D</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study</article-title>. <source>Health Qual Life Outcomes</source>
<year>2009</year>; <volume>7</volume>: <fpage>90</fpage>.<pub-id pub-id-type="pmid">19835583</pub-id></mixed-citation></ref><ref id="apt13334-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="apt13334-cit-0004">
<string-name>
<surname>Wahlqvist</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Karlsson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Carlsson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bolge</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Wallander</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Relationship between symptom load of gastro&#x02010;oesophageal reflux disease and health&#x02010;related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2008</year>; <volume>27</volume>: <fpage>960</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">18315585</pub-id></mixed-citation></ref><ref id="apt13334-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="apt13334-cit-0005">
<string-name>
<surname>El&#x02010;Serag</surname>
<given-names>HB</given-names>
</string-name>, <string-name>
<surname>Sweet</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Winchester</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Dent</surname>
<given-names>J</given-names>
</string-name>. <article-title>Update on the epidemiology of gastro&#x02010;oesophageal reflux disease: a systematic review</article-title>. <source>Gut</source>
<year>2014</year>; <volume>63</volume>: <fpage>871</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">23853213</pub-id></mixed-citation></ref><ref id="apt13334-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="apt13334-cit-0006">
<string-name>
<surname>Jung</surname>
<given-names>HK</given-names>
</string-name>. <article-title>Epidemiology of gastroesophageal reflux disease in Asia: a systematic review</article-title>. <source>J Neurogastroenterol Motil</source>
<year>2011</year>; <volume>17</volume>: <fpage>14</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">21369488</pub-id></mixed-citation></ref><ref id="apt13334-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="apt13334-cit-0007">
<string-name>
<surname>Pilichiewicz</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Horowitz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Holtmann</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Talley</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Feinle&#x02010;Bisset</surname>
<given-names>C</given-names>
</string-name>. <article-title>Relationship between symptoms and dietary patterns in patients with functional dyspepsia</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2009</year>; <volume>7</volume>: <fpage>317</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">18929687</pub-id></mixed-citation></ref><ref id="apt13334-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="apt13334-cit-0008">
<string-name>
<surname>Portale</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hsieh</surname>
<given-names>CC</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>When are reflux episodes symptomatic?</article-title>
<source>Dis Esophagus</source>
<year>2007</year>; <volume>20</volume>: <fpage>47</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">17227310</pub-id></mixed-citation></ref><ref id="apt13334-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="apt13334-cit-0009">
<string-name>
<surname>Kahrilas</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>McColl</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>M</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>The acid pocket: a target for treatment in reflux disease?</article-title>
<source>Am J Gastroenterol</source>
<year>2013</year>; <volume>108</volume>: <fpage>1058</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">23629599</pub-id></mixed-citation></ref><ref id="apt13334-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="apt13334-cit-0010">
<string-name>
<surname>Rohof</surname>
<given-names>WO</given-names>
</string-name>, <string-name>
<surname>Bennink</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Boeckxstaens</surname>
<given-names>GE</given-names>
</string-name>. <article-title>Proton pump inhibitors reduce the size and acidity of the acid pocket in the stomach</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2014</year>; <volume>12</volume>: <fpage>1101</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">24726906</pub-id></mixed-citation></ref><ref id="apt13334-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="apt13334-cit-0011">
<string-name>
<surname>Carlsson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Dent</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Watts</surname>
<given-names>R</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Gastro&#x02010;oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group</article-title>. <source>Eur J Gastroenterol Hepatol</source>
<year>1998</year>; <volume>10</volume>: <fpage>119</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">9581986</pub-id></mixed-citation></ref><ref id="apt13334-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="apt13334-cit-0012">
<string-name>
<surname>Dean</surname>
<given-names>BB</given-names>
</string-name>, <string-name>
<surname>Gano</surname>
<given-names>AD</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Knight</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ofman</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Fass</surname>
<given-names>R</given-names>
</string-name>. <article-title>Effectiveness of proton pump inhibitors in nonerosive reflux disease</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2004</year>; <volume>2</volume>: <fpage>656</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">15290657</pub-id></mixed-citation></ref><ref id="apt13334-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="apt13334-cit-0013">
<string-name>
<surname>Lai</surname>
<given-names>IR</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>M&#x02010;S</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>J&#x02010;T</given-names>
</string-name>. <article-title>Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy&#x02010;negative reflux disease</article-title>. <source>World J Gastroenterol</source>
<year>2006</year>; <volume>12</volume>: <fpage>747</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">16521188</pub-id></mixed-citation></ref><ref id="apt13334-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="apt13334-cit-0014">
<string-name>
<surname>Manabe</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>M</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial</article-title>. <source>Dis Esophagus</source>
<year>2012</year>; <volume>25</volume>: <fpage>373</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">22050449</pub-id></mixed-citation></ref><ref id="apt13334-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="apt13334-cit-0015">
<string-name>
<surname>Mandel</surname>
<given-names>KG</given-names>
</string-name>, <string-name>
<surname>Daggy</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Brodie</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Jacoby</surname>
<given-names>HI</given-names>
</string-name>. <article-title>Review article: alginate&#x02010;raft formulations in the treatment of heartburn and acid reflux</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2000</year>; <volume>14</volume>: <fpage>669</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">10848650</pub-id></mixed-citation></ref><ref id="apt13334-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="apt13334-cit-0016">
<string-name>
<surname>Malmud</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Charkes</surname>
<given-names>ND</given-names>
</string-name>, <string-name>
<surname>Littlefield</surname>
<given-names>J</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>The mode of action alginic acid compound in the reduction of gastroesophageal reflux</article-title>. <source>J Nucl Med</source>
<year>1979</year>; <volume>20</volume>: <fpage>1023</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">231639</pub-id></mixed-citation></ref><ref id="apt13334-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="apt13334-cit-0017">
<string-name>
<surname>Washington</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Steele</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Washington</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bush</surname>
<given-names>D</given-names>
</string-name>. <article-title>Patterns of food and acid reflux in patients with low&#x02010;grade oesophagitis&#x02013;the role of an anti&#x02010;reflux agent</article-title>. <source>Aliment Pharmacol Ther</source>
<year>1998</year>; <volume>12</volume>: <fpage>53</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">9692701</pub-id></mixed-citation></ref><ref id="apt13334-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="apt13334-cit-0018">
<string-name>
<surname>Dettmar</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Sykes</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Little</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Bryan</surname>
<given-names>J</given-names>
</string-name>. <article-title>Rapid onset of effect of sodium alginate on gastro&#x02010;oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes</article-title>. <source>Int J Clin Pract</source>
<year>2006</year>; <volume>60</volume>: <fpage>275</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">16494641</pub-id></mixed-citation></ref><ref id="apt13334-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="apt13334-cit-0019">
<string-name>
<surname>Chevrel</surname>
<given-names>B</given-names>
</string-name>. <article-title>A comparative crossover study on the treatment of heartburn and epigastric pain: liquid Gaviscon and a magnesium&#x02013;aluminium antacid gel</article-title>. <source>J Int Med Res</source>
<year>1980</year>; <volume>8</volume>: <fpage>300</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">6250928</pub-id></mixed-citation></ref><ref id="apt13334-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="apt13334-cit-0020">
<string-name>
<surname>Pouchain</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bigard</surname>
<given-names>M&#x02010;A</given-names>
</string-name>, <string-name>
<surname>Liard</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Childs</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Decaudin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McVey</surname>
<given-names>D</given-names>
</string-name>. <article-title>Gaviscon vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial</article-title>. <source>BMC Gastroenterol</source>
<year>2012</year>; <volume>12</volume>: <fpage>18</fpage>.<pub-id pub-id-type="pmid">22361121</pub-id></mixed-citation></ref><ref id="apt13334-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="apt13334-cit-0021">
<string-name>
<surname>Hampson</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Jolliffe</surname>
<given-names>IG</given-names>
</string-name>, <string-name>
<surname>Bakhtyari</surname>
<given-names>A</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Alginate&#x02010;antacid combinations: raft formation and gastric retention studies</article-title>. <source>Drug Dev Ind Pharm</source>
<year>2010</year>; <volume>36</volume>: <fpage>614</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">19925256</pub-id></mixed-citation></ref><ref id="apt13334-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="apt13334-cit-0022">
<article-title>Gaviscon Double Action: Summary of Product Characteristics</article-title>. Last revised 28/01/2011. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/medicine/20053">https://www.medicines.org.uk/emc/medicine/20053</ext-link> (accessed 22 January 15).</mixed-citation></ref><ref id="apt13334-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="apt13334-cit-0023">
<string-name>
<surname>Kwiatek</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Roman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fareeduddin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pandolfino</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Kahrilas</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>An alginate&#x02010;antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial &#x02018;acid pocket&#x02019; in symptomatic GERD patients</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2011</year>; <volume>34</volume>: <fpage>59</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">21535446</pub-id></mixed-citation></ref><ref id="apt13334-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="apt13334-cit-0024">
<string-name>
<surname>Rohof</surname>
<given-names>WO</given-names>
</string-name>, <string-name>
<surname>Bennink</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Smout</surname>
<given-names>AJPM</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Boeckxstaens</surname>
<given-names>GE</given-names>
</string-name>. <article-title>An alginate&#x02010;antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2013</year>; <volume>11</volume>: <fpage>1585</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">23669304</pub-id></mixed-citation></ref><ref id="apt13334-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="apt13334-cit-0025">
<string-name>
<surname>De Ruigh</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Roman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pandolfino</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Kahrilas</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Gaviscon Double Action Liquid (antacid &#x00026; alginate) is more effective than antacid in controlling post&#x02010;prandial oesophageal acid exposure in GERD patients: a double&#x02010;blind crossover study</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2014</year>; <volume>40</volume>: <fpage>531</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">25041141</pub-id></mixed-citation></ref><ref id="apt13334-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="apt13334-cit-0026">
<string-name>
<surname>Thomas</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Wade</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Crawford</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Jenner</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Levinson</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>J</given-names>
</string-name>. <article-title>Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket&#x02010;targeting alginate&#x02010;antacid (Gaviscon Double Action) &#x02013; a double&#x02010;blind, placebo&#x02010;controlled, pilot study in gastro&#x02010;oesophageal reflux disease</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2014</year>; <volume>39</volume>: <fpage>595</fpage>&#x02013;<lpage>602</lpage>.<pub-id pub-id-type="pmid">24471505</pub-id></mixed-citation></ref><ref id="apt13334-bib-0027"><label>27</label><mixed-citation publication-type="miscellaneous" id="apt13334-cit-0027">
<article-title>Study details on the Clinical.gov trial registry website</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01869491">https://clinicaltrials.gov/ct2/show/NCT01869491</ext-link> (accessed 22 January 15).</mixed-citation></ref><ref id="apt13334-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="apt13334-cit-0028">
<string-name>
<surname>Shaw</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Talley</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Beebe</surname>
<given-names>TJ</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease</article-title>. <source>Am J Gastroenterol</source>
<year>2001</year>; <volume>96</volume>: <fpage>52</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11197287</pub-id></mixed-citation></ref><ref id="apt13334-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="apt13334-cit-0029">
<string-name>
<surname>Jaeschke</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Singer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Guyatt</surname>
<given-names>GH</given-names>
</string-name>. <article-title>Measurement of health status. Ascertaining the minimal clinically important difference</article-title>. <source>Control Clin Trials</source>
<year>1989</year>; <volume>10</volume>: <fpage>407</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">2691207</pub-id></mixed-citation></ref><ref id="apt13334-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="apt13334-cit-0030">
<string-name>
<surname>Juniper</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Guyatt</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Willan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Griffith</surname>
<given-names>LE</given-names>
</string-name>. <article-title>Determining a minimal important change in a disease&#x02010;specific Quality of Life Questionnaire</article-title>. <source>J Clin Epidemiol</source>
<year>1994</year>; <volume>47</volume>: <fpage>81</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">8283197</pub-id></mixed-citation></ref><ref id="apt13334-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="apt13334-cit-0031">
<string-name>
<surname>Cao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>XQ</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Validation of a survey methodology for gastroesophageal reflux disease in China</article-title>. <source>BMC Gastroenterol</source>
<year>2008</year>; <volume>8</volume>: <fpage>37</fpage>.<pub-id pub-id-type="pmid">18717991</pub-id></mixed-citation></ref><ref id="apt13334-bib-0032"><label>32</label><mixed-citation publication-type="miscellaneous" id="apt13334-cit-0032">
<article-title>Reckitt Benckiser Healthcare (UK) Ltd. 0900901 study data on file</article-title>.</mixed-citation></ref><ref id="apt13334-bib-0033"><label>33</label><mixed-citation publication-type="miscellaneous" id="apt13334-cit-0033">
<article-title>Reckitt Benckiser Healthcare (UK) Ltd. GA0917 study data on file</article-title>.</mixed-citation></ref><ref id="apt13334-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="apt13334-cit-0034">
<string-name>
<surname>DeVault</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Castell</surname>
<given-names>DO</given-names>
</string-name>. <article-title>American College of G. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease</article-title>. <source>Am J Gastroenterol</source>
<year>2005</year>; <volume>100</volume>: <fpage>190</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">15654800</pub-id></mixed-citation></ref><ref id="apt13334-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="apt13334-cit-0035">
<string-name>
<surname>Cremonini</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ziogas</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>HY</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Meta&#x02010;analysis: the effects of placebo treatment on gastro&#x02010;oesophageal reflux disease</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2010</year>; <volume>32</volume>: <fpage>29</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">20353496</pub-id></mixed-citation></ref></ref-list></back></article>